Research Article
Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer
Table 3
NGAL and MMP-9 concentration levels in patients with or without endometrial cancer risk factors.
| | NGAL
pg/ml | MMP-9
ng/ml | |
| | Obesity | 230 (170–254) | 7234.5 (6345–8234) | Mean range | | Without obesity | 150 (110–188) | 7465.6 (6234–8767) | | 0.001 | >0.05 | | | Diabetes t2 | 210 (148–243) | 7632.3 (7142–8111) | Mean range | | Without diabetes t2 | 132 (103–163) | 7231.4 (6721–8082) | | 0.002 | >0.05 | | | Hypertension | 189 (138–201) | 6721.1 (6234.6–7341.3) | Mean range | | Without hypertension | 160 (131–192) | 7561.4 (7098–8212) | | >0.05 | >0.05 | |
|
|
